The author recounts their experience with cosmetic treatments, realizing they were receiving Dysport instead of Botox. This reflects a broader trend where competitors like Xeomin and Jeuveau are gaining market share, challenging Botox’s dominance. AbbVie, facing a projected sales drop, seeks innovation to retain its significant revenue source.













